- Home
- PDS vs CAPR Comparison
PDS vs CAPR Comparison
Compare PDS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDS
- CAPR
- Stock Information
- Founded
- PDS 1951
- CAPR 2005
- Country
- PDS Canada
- CAPR United States
- Employees
- PDS N/A
- CAPR N/A
- Industry
- PDS
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDS
- CAPR Health Care
- Exchange
- PDS Nasdaq
- CAPR Nasdaq
- Market Cap
- PDS 998.3M
- CAPR 867.6M
- IPO Year
- PDS N/A
- CAPR N/A
- Fundamental
- Price
- PDS $56.68
- CAPR $12.52
- Analyst Decision
- PDS Buy
- CAPR Strong Buy
- Analyst Count
- PDS 1
- CAPR 7
- Target Price
- PDS $95.00
- CAPR $39.29
- AVG Volume (30 Days)
- PDS 64.3K
- CAPR 1.5M
- Earning Date
- PDS 02-04-2025
- CAPR 11-13-2024
- Dividend Yield
- PDS N/A
- CAPR N/A
- EPS Growth
- PDS 62.11
- CAPR N/A
- EPS
- PDS 12.37
- CAPR N/A
- Revenue
- PDS $1,436,787,445.00
- CAPR $23,228,045.00
- Revenue This Year
- PDS $2.90
- CAPR N/A
- Revenue Next Year
- PDS $3.01
- CAPR $74.85
- P/E Ratio
- PDS $4.63
- CAPR N/A
- Revenue Growth
- PDS N/A
- CAPR 65.33
- 52 Week Low
- PDS $51.53
- CAPR $3.52
- 52 Week High
- PDS $79.07
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- PDS 34.39
- CAPR 34.06
- Support Level
- PDS $58.32
- CAPR $13.00
- Resistance Level
- PDS $61.71
- CAPR $20.75
- Average True Range (ATR)
- PDS 1.71
- CAPR 1.67
- MACD
- PDS -0.49
- CAPR -0.36
- Stochastic Oscillator
- PDS 3.79
- CAPR 3.18
About PDS Precision Drilling Corporation
Precision Drilling Corpd is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.